Email updates

Keep up to date with the latest news and content from CCS and BioMed Central.

Open Access Highly Accessed Review

Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers

Reza Ehsanian123*, Carter Van Waes1 and Stephan M Feller3

Author Affiliations

1 Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, MD, USA

2 Stanford University School of Medicine, Stanford, CA, USA

3 Cell Signalling Group, Department of Molecular Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford University, Headley Way, Oxford OX3 9DS, UK

For all author emails, please log on.

Cell Communication and Signaling 2011, 9:13  doi:10.1186/1478-811X-9-13

Published: 15 May 2011

Abstract

This is an in-depth review of the history of quinacrine as well as its pharmacokinetic properties and established record of safety as an FDA-approved drug. The potential uses of quinacrine as an anti-cancer agent are discussed with particular attention to its actions on nuclear proteins, the arachidonic acid pathway, and multi-drug resistance, as well as its actions on signaling proteins in the cytoplasm. In particular, quinacrine's role on the NF-κB, p53, and AKT pathways are summarized.